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Abstract
Uncoupling protein 2 (UCP2) is an inner mitochondrial membrane protein. Although the protein was discovered in 1997, its
function and even its tissue distribution are still under debate. Here we present a quantitative analysis of mRNA and protein
expression in various mice tissues, revealing that UCP2 is mainly expressed in organs and cells associated with the immune
system. Although the UCP2 gene is present in the brain, as demonstrated using quantitative RT-PCR, the protein was not
detectable in neurons under physiological conditions. Instead, we could detect UCP2 in microglia, which act in the immune
defense of the central nervous system. In lymphocytes, activation led to a ten-fold increase of UCP2 protein expression
simultaneously to the increase in levels of other mitochondrial proteins, whereas lymphocyte re-stimulation resulted in the
selective increase of UCP2. The highest detected level of UCP2 expression in stimulated T-cells (0.54 ng/(mg total cellular
protein)) was approximately 200 times lower than the level of UCP1 in brown adipose tissue from room temperature
acclimated mice. Both the UCP2 expression pattern and the time course of up-regulation in stimulated T-cells imply UCP2’s
involvement in the immune response, probably by controlling the metabolism during cell proliferation.
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Introduction
Uncoupling protein 2 (UCP2) is an inner mitochondrial
membrane protein, which belongs to the mitochondrial anion
carrier superfamily [1,2] and is highly homologous to UCP3 (73%)
and UCP1 (59%, [3]). The latter mediates non-shivering
thermogenesis in brown adipose tissue (BAT) by dissipating
a proton gradient across the inner mitochondrial membrane [4–
6]. Although UCP2 was discovered in 1997, its transport function
is still under debate. Experiments using artificial membranes
support the idea that UCP2 transports protons in the presence of
fatty acids and with high sensitivity to the membrane potential
similarly to UCP1 [7–10]. However, there is still no convincing
evidence from cells or isolated mitochondria that the uncoupling
properties of UCP2 can be compared to those of UCP1. A possible
explanation may be the difference in the expression levels of these
proteins [11].
Unlikely to UCP1 and other UCPs, UCP2 mRNA was detected
in all tissues tested [3,12–15]. In contrast to mRNA, protein
expression has been described in few tissues and tissue distribution
reported by different laboratories varies. One group reported the
UCP2 expression in spleen, lungs, stomach, intestine, white
adipose tissue (WAT) but not in muscle, heart, liver, kidney, BAT
and brain [16,17], while other laboratories have found UCP2 in
pancreatic islet cells [18], thymocytes [19] and kidney [20].
Turner et al. [21] detected UCP2 in cardiomyocytes. Several
research groups revealed the presence of UCP2 in distinct brain
regions [22–24]. Possible reason for the discrepancies are the
different animal models used, the age of the animals, the quality of
the antibodies used and the extremely short half-life time of the
protein [25].
Despite the fact that UCP2 expression in brain has not been
clearly demonstrated, UCP2 is increasingly associated with
a neuroprotective function [26–31]. Sometimes such conclusion
has been supported by artificial overexpression of UCP2 [32] that
may not correctly reflect normal tissue distribution. Many previous
observations were done using UCP2 knockout mice on mixed
genetic background [18,33]. An increase of UCP2 mRNA levels in
the course of mice experimental autoimmune encephalomyelitis
[34] was reported, however, it could not be determined whether
UCP2 is increased due to spinal cord infiltration by immune cells
or as a result of neuronal expression of UCP2.
The first functional connection between UCP2 and immune
system was established when the UCP2 knockout mouse was
found to show an elevated immune response to pathogens [33]. An
increasing number of reports demonstrate that macrophages and
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mast cells from the UCP2 knockout mouse have higher levels of
cytokines or histamine, are more active by infiltration and produce
more reactive oxygen species (ROS) [35–38]. The analysis of
UCP2 levels after macrophages activation [39] revealed that
UCP2 expression is reduced after stimulation with lipopolysac-
charide (LPS) for 24 hours. No results concerning UCP2
regulation at later time points after stimulation were reported. In
contrast, in vivo studies showed up-regulation of UCP2 after LPS
treatment, explaining the discrepancy between in vitro and in vivo
studies by existing of two, early and late, stages of the immune cell
response [40]. It is possible that other cells beside immune cells
contribute to the UCP2 expression in the studies in vivo. The
regulation of the UCP2 expression in stimulated T-cells is still not
investigated. It is also unclear, whether UCP2 abundance varies
selectively or simultaneously to other mitochondrial proteins.
In the present work we investigate UCP2 expression among
different mouse tissues at the mRNA and protein levels focusing
on cells of the nervous and immune systems. For this, we
generated new antibodies that had given the correct results with
recombinant UCP2 and the UCP2 knockout mouse. To test the
hypothesis that UCP2 up-regulation in brain during inflammation
may be explained by enhanced protein expression in immuno-
competent cells (housing and/or invaded) rather than in neurons,
we compared the expression of UCP2 at different activation stages
of lymphocytes.
Methods
Chemicals
All chemicals were obtained from Sigma-Aldrich (Austria),
Merck (Austria) or Lactan (Austria), unless otherwise indicated.
Animals and Tissue Samples
Native C57BL/6 mice aged 5 days, 30 days, 5 months and
12 months were purchased from Charite´ – Universita¨tsmedizin’s
central animal facility (FEM) (Berlin, Germany) or Charles River
(Sulzfeld, Germany). Animals were deeply anaesthetised with
a mixture containing ketamine (Pfizer, Germany) and xylazine
(Rompun@, Bayer, Germany) and sacrificed by decapitation as
previously described [41]. Brain, spinal cord, thymus, heart, testis,
white adipose tissue, skeletal muscles, lung, spleen, lymph nodes,
stomach, intestine, liver, and kidney were removed, frozen in
liquid nitrogen and stored at 280uC until protein or RNA
isolation was performed. All procedures in this study were
performed in accordance with the European Communities
Council Directive from November 24th, 1986 (86/609/EEC).
Male C57Bl/6 mice lacking UCP2 (UCP22/2) and their wild
type controls aged 10–12 weeks were derived from those described
in [33]. The UCP22/2 mice used in this study were backcrossed
for more than 10 generations onto a C57Bl/6 background.
Animals were maintained on a 12:12 h light-dark cycle (light from
7 a.m. to 7 p.m.), at 24uC and were allowed unlimited access to
standard laboratory chow and tap water. All experiments were
approved by the Animal Ethics Committee of the North Stock-
holm region.
Magnetic Immune Cell Separation
Mononuclear splenocytes were isolated on Histopaque gradient
from three independent native C57BL/6 mice. Monocytes, T-cells
and B cells from C57BL/6 mouse spleen were positively selected
by magnetic cell separation using MACS-beads (Miltenyi Biotec,
Germany) coated with antibodies against CD11b, CD4 and
CD19, respectively. NK cells were negatively selected using NK
cell isolation kits (Miltenyi Biotec, Germany). Cell populations
were sorted according to the manufacturer’s instructions and
yielded .95% purity. After sorting, washing and counting,
immune cells were processed immediately for protein extraction
as described previously [41].
Primary Brain Cell Cultures
Cortical neuron, astrocyte and microglia cultures were prepared
as previously described [41]. For RNA and protein isolation,
neurons were harvested after 11–12 days, astrocytes and microglia
after 13–21 days.
Isolation and Activation of OT-II T-cells
We used naive T-cell-receptor transgenic T-cells (background
C57BL/6) specific for the ovalbumin peptide OVA323–339 (OT-
II T-cells) because of their clonal nature and specificity to an
exogenous antigen. OT-II T-cells were magnetically sorted using
anti-CD4-MACS beads according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Germany) and primed in vitro with
OVA323–339 (Pepceuticals, UK) presented by sorted irradiated
antigen-presenting cells (APC) at a ratio of 1:10 (T-cells: APC). T-
cells and APC were cultured in 36 106/ml cell culture medium
(RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and 10% foetal calf serum) for
7 days. Thereafter, viable OT-II cells were isolated by density
gradient centrifugation with Histopaque-1077 (Sigma-Aldrich,
USA). T-lymphocytes were re-stimulated at day 7 after the first
stimulation for the maintaining of high cell activity. On day 3 and
5, T-cells were splitted with fresh medium containing IL-2
(100 U/ml). To avoid the presence of APC-derived proteins in
Western blot analyses, OT-II cells were re-stimulated without
APC using coated anti-CD3 and anti-CD28 antibodies (BD
Biosciences, Germany) and analysed after 6, 24 hours and 2, 3, 4,
7, 10 and 14 days. The second re-stimulation was performed
identically 7 days after the first re-stimulation. After various
periods of activation, T-cells were processed for protein extraction
as described below. In cultures, in which expression analyses were
performed from day 0, OT-II T-cells were activated with aCD3/
aCD28 antibodies from the first day on in order to avoid APC
contamination in the Western blot analyses as mentioned above.
Isolation and Activation of Wild Type CD4 and CD8 T-
cells
CD4 and CD8 T-cells were magnetically sorted from C57BL/6
splenocytes using anti-CD4 and anti-CD8 MACS beads, re-
spectively according to the manufacturer’s instructions (Miltenyi
Biotec, Germany). CD4 and CD8 T-cells were primed in vitro
with plate-bound aCD3/aCD28 antibodies and analysed after 6,
24 hours and 2, 3, 4, and 7 days as described above.
To rule out potential effects of the culturing medium containing
glutamine and IL-2 on the expression of UCP2, CD4 T-cells were
cultured in the absence of aCD3/aCD28 antibodies with IL-2
(100 U/ml) added on day 0 h and at 72 h using standard medium,
i.e. RPMI 1640 supplemented with 2 mM L-glutamine and
antibiotics. Expression of UCP2 was monitored at 24 hours and on
day 2, 3 and 4 after stimulation (Fig. S1C).
Quantitative RT-PCR
Mouse organs obtained from six independent animals for each
of the investigated ages were snap-frozen immediately after
extraction in liquid nitrogen. Mouse tissues and primary mouse
brain cells (neurons, astrocytes and microglia) were homogenized
in TRIzol reagent (Invitrogen). Total RNA was purified according
the TRIzol protocol. RNA concentrations were determined at
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wavelength 260 nm using a Biomate 3 Spectrometer (Fisher
Scientific, USA). A ‘‘High Capacity cDNA Reverse Transcription
kit’’ (Applied Biosystems, USA) was used to generate total cDNA
for the real-time PCR using 5 mg total RNA from each sample
according to the manufacturer’s recommendations.
Each PCR reaction contained: 8 ml H2O, 10 ml TaqManH Fast
Universal PCR Master Mix (Applied Biosystems, USA), 1 ml
cDNA and 1 ml TaqMan Gene Expression Assays. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), ß-actin and HRPT
(hypoxanthine-guanine phosphoribosyltransferase) were used as
internal controls. Assays ID 4352932E and ID 4352933E were
used for GAPDH and b-Actin respectively. For HPRT separate
primers and probes were used (Primer Mix (for 59-ATCAT-
TATGCCGAGGATTTGGAA-39; rev 59-TTGAGCACACA-
GAGGGCCA-39) and probe (59-TGGACAGGACTGAAA-
GACTTGCTCGAGATG-39). The investigated TaqMan Gene
Expression Assays was UCP2 (uncoupled protein 2, Assay ID
627598 m1). To determine the relative gene expression in each
experiment samples were double-tested and one ‘no template’
control (NTC) was used. Each result is the average of three
separate experiments. All transcripts (within each set of specimens)
were always analysed within the same experiment. Amplification
and fluorescence detection were conducted with the ABI
PRISMTM 7700 Sequence Detection System (Applied Biosystems).
The fluorescence threshold value was calculated using the ABI
PRISMTM 7700 System Software.
For the quantitative comparison of the UCP2 gene expression,
data extracted from each qRT-PCR run were analyzed using the
7500 Fast System software (Applied Biosystems, Foster City, CA,
USA). The value of the noise fluorescence, usually indicated as the
base line of the run, was automatically determined. The threshold
value was manually set to 0.05. The CT was automatically
calculated and used to quantify the starting copy number of the
target mRNA. Normalization of UCP2 gene in tissue and cells was
carried out to internal control of GAPDH, ß-actin and, HPRT
expression by means of the 2-dCT method [42].
Western Blot Analysis
The collection of total cellular protein from tissue samples and
Western blot analysis was performed as described previously [41]
with some modifications. Per lane 20–50 mg of protein were
loaded. Membranes were incubated at 4uC in block solution (1x
TBS-buffer; 2% BSA; 0.05% Tween 20; 0.02% Thimerosal) for at
least 12 hours. Samples were incubated with UCP2 (s. Results)
antibodies (diluted 1:2000) in block solution for up to two days at
4uC. As secondary antibody, horseradish peroxidase-linked
antibody (GE Healthcare, Austria) was used. Immunoreaction
was visualized with luminescence from ECL Western Blotting
reagent (GE Healthcare, Austria) used according manufacturer’s
instructions and measured with the ChemiDoc-It 600 Imaging
System (UVP, UK). For protein loading controls, membranes were
incubated with specific antibodies against VDAC (Abcam,
ab14734, dilution 1:5000), Hsp60 (heat shock protein, Abcam,
dilution 1:10000), SDHA (succinate dehydrogenase complex,
subunit A, Abcam, dilution 1:10000), b-Actin (Sigma-Aldrich,
A5441, dilution 1:5000) or GAPDH (Sigma-Aldrich, G8795,
dilution 1:10000) in block solution for at least one hour.
Results
UCP2 mRNA Expression Pattern
Although all previous studies have shown that UCP2 mRNA is
ubiquitously distributed, the reported levels vary considerably
between tissues. To test whether age differences may have
contributed to the discrepancies in results, we compared UCP2
mRNA expression in different tissues of early postnatal (5 days
old), young (30 days old) and adult (12 months old) C57BL/6 mice
(Fig. 1). mRNA levels were determined by quantitative real-time
PCR-analysis and presented as ratios of UCP2 to the housekeep-
ing gene GAPDH. We detected the highest UCP2 mRNA
expression in spleen with mRNA levels (1.1360.57) times those
of GADPH. Thymus, lung and stomach showed slightly lower
mRNA levels at 0.4060.09, 0.3860.05 and 0.5760.33, re-
spectively. UCP2 mRNA levels determined in WAT and kidney
were 0.1360.10 and 0.0760.02. The lowest UCP2 mRNA levels
were measured in skeletal muscle (0.00160.0005), whole brain
(0.01360.002) and spinal cord (0.0260.01). Notably, UCP2
mRNA levels in most investigated tissues, including brain, heart,
lungs, kidney and especially liver, are down-regulated in adult
mice compared to early postnatal age. Exceptions are the spleen
and thymus, in which we observed an increase of UCP2 mRNA
levels with aging. Although some of our mRNA analysis is in
agreement with the observation of other groups [14] no such
tendency has been reported previously. UCP2 mRNA levels
compared to b-actin show comparable results (data not shown).
Antibody Generation and Validation
To obtain specific antibodies against UCP2, two peptides, (1)
‘‘VGFKATDVPPTATVKF’’ (homologous to the mouse UCP2
N-terminus) and (2) ‘‘DSVKQFYTKGSEHAGIGSR’’ (homolo-
gous to the first innermembrane space loop of mouse UCP2) were
synthesized. 180 days after rabbit immunization, serum was
affinity purified and tested in Western Blots, using recombinant
mUCP1 [10], hUCP2 [10], mUCP4-gfp, mUCP5 [41] and tissue
samples from UCP2 knockout mice. Synthesis of peptides,
immunization of rabbits and affinity purification of serum,
containing UCP2 was performed by PINEDA Antibody-Service
GmbH (Berlin, Germany). Only the antibody generated using the
peptide ‘‘VGFKATDVPPTATVKF’’ recognized the recombinant
Figure 1. Quantitative analysis of UCP2 mRNA distribution in
various tissues by real-time PCR in 5 day, 30 day and 12 month
old mice. UCP2 mRNA levels are represented as ratios to the mRNA
level of the housekeeping gene GAPDH. UCP2 mRNA in stomach,
skeletal muscle, spinal cord and WAT was measured only in 12 month
old mice. Each data point represents the mean value 6 SD of 3–6 mice.
doi:10.1371/journal.pone.0041406.g001
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UCP2 and showed no cross reaction with other recombinant
proteins. No protein recognition was observed if tissues from the
UCP2 knockout mouse were used (Fig. 2B).
UCP2 Distribution at the Protein Level
To compare UCP2 mRNA and protein levels, we performed
Western blot analysis using the same tissue samples. In thymus,
spleen, lungs and stomach tissue of 12 month old mice we detected
bands at the same position as that of recombinant UCP2 (Fig. 2A).
We verified these bands by analysis of UCP2 knockout mouse
tissues (Fig. 2B). Under the same conditions we detected UCP2 in
intestine, colon (data not shown), but did not find bands
corresponding to UCP2 in brain, liver, BAT, skeletal muscle or
heart. The observed expression pattern matches the reported
mRNA levels in these tissues and is generally in accordance with
the analysis published in [16]. To test the hypothesis that UCP2 is
abundant in all organs of the immune system, we additionally
investigated lymph nodes (Fig. 2C), where we also detected
a significant level of UCP2 expression. The expression in testis
(data not shown), kidney and brain was rather sporadic (Fig. 2).
We could not distinguish, whether UCP2 is expressed in functional
cells of these organs or whether the signal we observed was caused
by housing immune cells.
Whereas 30 days old mice showed a similar pattern of UCP2
protein expression in Western blot analysis as that of adult mice
(data not shown), we detected an additional slight but stable
protein expression in kidney, heart and liver (Fig. 2D) of early
postnatal mice (5 days old). The expression in liver may be
explained by the presence of erythroblasts due to foetal
erythropoiesis [43]. No significant UCP2 expression in whole
brain was found in any of the age groups examined.
UCP2 Expression in Regions of the Central Nervous
System
It was previously described that UCP2 expression in brain is
restricted to particular regions, such as the supraoptic, paraven-
tricular, suprachiasmatic and arcuate nuclei of the hypothalamus
[22]. To test whether UCP2 expression is specific to these defined
regions of the brain, we investigated the neocortex, hippocampus,
cerebellum, brain stem and spinal cord for mRNA and protein
Figure 2. Representative Western blot analysis showing UCP2 expression in different tissues from 12 month old mice (A), UCP2
knockout mice and their wild type controls aged 10–12 weeks (B) and 5 day old mice (D). Analysis of UCP2 protein expression in lymph
nodes from 12 week old mice (C). Gels were loaded with 50 mg protein per lane. Recombinant human UCP2 was used as a control. At least six mice
were analysed at each condition.
doi:10.1371/journal.pone.0041406.g002
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expression. Figure 3A shows the distribution of UCP2 mRNA at
similar levels in neocortex (0.01260.005), hippocampus
(0.01360.005), cerebellum (0.01760.002), brain stem
(0.01960.005) and spinal cord (0.02360.003) related to the
housekeeping genes GAPDH or HRPT (data not shown). Using
Western Blots we detected no differences in the levels of UCP2
protein expression between cortex, cerebellum, brain stem and
spinal cord. Only at prolonged developmental times for detection
of chemiluminescence and with larger amounts of total protein
applied (50–100 mg) did we occasionally obtain a barely visible
signal for UCP2 protein expression in the regions tested. Figure 3B
shows the best example for the Western Blot. Interestingly,
although UCP2 mRNA was detectable (Fig. 3A), UCP2 protein
level seems to be very low. Based on these data we hypothesized
that the traces of UCP2 could be due to the presence of microglia
rather than due to UCP2 expression in neuronal cells as previously
reported at the mRNA level [26,44].
Analysis of UCP2 Expression in Brain Cells
To test whether UCP2 can be assigned to microglia, we
analysed UCP2 expression in isolated brain cells. Primary cell
cultures of neurons, astrocytes and microglial cells were prepared
from murine cortex (including hippocampus). Quantitative anal-
ysis showed the highest UCP2 mRNA level in microglia
(0.32660.012, Fig. 4A), followed by astrocytes (0.0560.02) and
neurons (0.3560.16)*1023. The level in microglia can be
compared with the expression in thymus, stomach and lungs
(Fig. 1). UCP2 mRNA level in neurons is approximately 50 times
lower than that of different regions of the brain (Fig. 1, Fig. 3A).
Based on this mRNA distribution, we suggest that only microglia
express UCP2 protein at detectable levels. Western blot analysis
confirmed our suggestion: significant amounts of protein were
revealed in microglia cells even by application of 20 mg total
protein and to a lesser extent in astrocytes (Fig. 4B). No UCP2
protein was detected in neurons.
Analysis of UCP2 Protein Expression in Immune Cells
After we have demonstrated the preferential UCP2 expression
in lymphatic organs and brain microglia, we analyzed B-cells, T-
cells, monocytes and NK-cells (natural killer cells) isolated from
blood. Figure 4C reveals a strong protein expression in monocytes,
T- and B-cells and weaker expression in NK-cells. This finding
supports previous data showing UCP2 expression in B-cells, T-
cells, macrophages, dendritic cells and neutrophils [36].
Time Course of UCP2 Expression After Stimulation of T-
cells
To verify the involvement of UCP2 in immune system function
we monitored the protein expression during stimulation of OT-II
T-cells. UCP2 expression was analysed by Western Blot at several
time points after stimulation up to two weeks (Fig. 5). We detected
a significant up-regulation of protein within 24 hours following
stimulation (Fig. 5A), reaching a peak at 96 hours (Fig. 5B and
5D). Also the mitochondrial outer membrane protein VDAC,
mitochondrial matrix heat shock protein Hsp60 and mitochon-
drial inner membrane protein SDHA, which we analyzed
simultaneously, showed the similar expression patterns. Without
re-stimulation, UCP2 expression decreases from day seven after
stimulation. The first and second re-stimulation led to a further
increase of UCP2 protein expression. Interestingly, whereas
simultaneous increase of other mitochondrial proteins (VDAC,
Hsp6, SHDA) could be observed during stimulation, only UCP2 is
enhanced during re-stimulation (Fig. 5D). The time monitoring of
UCP2 expression shows that the modification of protein levels
starts several hours after cell activation. Because TCR-mediated
activation events occur fast (less than in a few hours) we concluded
that UCP2 increase is rather associated with T-cell metabolism
alteration and following strong proliferation than with cell
activation per se.
We measured similar UCP2 expression kinetics also for CD4
and CD8 T-cells from wild type mice activated with aCD3a/
CD28 (Fig. S1A and S1B), confirming that the observed up-
regulation of UCP2 is coupled to activation-induced proliferation
not only in TCR-transgenic CD4 cells but also in genetically not
manipulated C57Bl/6 CD4 and CD8 T cells. The highest UCP2
expression observed in re-stimulation experiment may be
explained by the highest proliferative and active state of the T-
cells with the maximal increased glycolytic metabolism.
Figure S1C shows that in the presence of IL-2 and in the
absence of activation via TCR no significant UCP2 increase was
observed, confirming our hypothesis that only cell activation
leading to the strong proliferation is associated with UCP2 up-
regulation.
Quantitative Analysis of UCP2 Expression
The large discrepancy between UCP2 mRNA and protein levels
motivated us to estimate the amount of UCP2 in tissues and to
compare them with those of UCP1. By loading of defined amounts
Figure 3. Comparison of UCP2 mRNA and protein levels in
different regions of the central nervous system. (A) UCP2 mRNA
determination in 5 month old mice. UCP2 values are presented as ratios
to the amount of GAPDH mRNA. Each data point represents the mean
6 SD of six mice. (B) The best example for UCP2 protein detection in
50 mg total cellular protein of various regions of the central nervous
system was performed in 5 month old mice.
doi:10.1371/journal.pone.0041406.g003
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of recombinant UCP2 and comparing of band intensities between
recombinant UCP2 and other tissues (spleen, thymus, stomach
and lung) of 12 month old mice we determined the proportion of
UCP2 in the whole cell protein extracts. The amount of UCP2
protein in tissues ranges from 0.04 to 0.17 ng/(mg of total cellular
protein) (Fig. 6A and 6B). In comparison the amount of UCP2 in
different isolated immune cell types was slightly higher at
approximately 0.05 ng/(mg of total cellular protein) in B-cells, T-
cells and monocytes. NK-cells have only 0.02 ng UCP2 per mg of
total cellular protein. Stimulation of T-cells leads to an approx-
imately 10-fold increase in the amount of UCP2 (Fig. 6A). In
contrast, we calculated approximately 128,4 ng/(mg of total
cellular protein) in BAT taken from 12 month old animals not
adapted to cold (Fig. 6C). This means that even in stimulated T-
cells the amount of UCP2 is 200 times lower than the level of
UCP1 in BAT.
Discussion
Using quantitative mRNA and Western blot analysis with
evaluated antibodies we determined a high UCP2 predominance
in mononuclear immune cells of adult mice at both mRNA and
protein levels. We confirmed protein expression in B-cells and T-
cells and extended the cellular UCP2 expression pattern to
monocytes, NK-cells and microglia cells. For the first time we have
shown that the stimulation of T-cells leads to an increase of UCP2
in mitochondria during the entire period after cell activation. In
contrast to the study of Kizaki et al. on macrophages [39] we
extended the period of T-cells investigation to three weeks,
including the first stimulation following by two re-stimulations.
The time course of UCP2 expression reveals that protein up-
regulation follows the stimulation pattern of T-cells, presumably
reflecting the enhanced metabolic demand due to rapid lympho-
cyte proliferation.
It is known that a bioenergetic situation changes dramatically
after T-cells become activated (for review [45]). Quiescent T-cells
utilize an energy-efficient oxidative metabolism to maintain basic
housekeeping but change to glycolysis when stimulated to promote
growth, proliferation, migration and effector function in the
presence of pathogens [19,46]. Lymphocytes in a state of high
biochemical activity demand a supply of high-energy nucleoside
triphosphates for the production of important molecules (cyto-
kines, antibodies, etc.) and the support of enhanced transport and
metabolic processes. Through the regulation of the Akt and Myc
signalling pathways, uptake of glucose and glutamine is initiated
for glycolysis and glutaminolysis respectively [47]. With regard to
UCP2, it was shown previously that glutamine abolishes the
inhibitory effect of a short upstream open reading frame (uORF,
[48]) and induces translation of UCP2 in a concentration-de-
pendent manner [49,50]. Cytokines are also known to alter the
abundance of UCP2 [51]. Therefore the transition of cellular
metabolism to glycolysis, leading to an increased glutamine
uptake, may simultaneously trigger UCP2 synthesis (for review
[52]).
The role of UCP2 during lymphocyte activation is uncertain.
However, it becomes more and more obvious that UCP2 is
expressed/up-regulated in cells generating ATP mainly by
glycolysis and showing a high proliferation rate. Recently it
was reported that in human pluripotent stem cells (hPSC)
UCP2 may regulate vigour metabolism by facilitating glycolysis
via substrate shunting mechanism and preventing glucose
oxidation in mitochondria [53]. It was suggested that hPSC
require UCP2 repression for full differentiation potential. The
comparison of hPSC and lymphocytes, which are fully
differentiated, supports the conclusion that UCP2 presence is
associated rather with fast proliferation and/or enhanced
transport and metabolic processes than with differentiation.
This conclusion is in agreement with previous studies in murine
embryonic fibroblasts [54] and in bone marrow progenitor cells
[43] reporting that the absence of UCP2 or decrease of its level
is deleterious for cell proliferation.
UCP2 function at molecular level may be to maintain
mitochondrial potential sufficiently low to prevent mitochondrial
hyperpolarization [55]. The latter is triggered by T-cell receptor
Figure 4. Comparison of UCP2 mRNA (A) and protein content (B) in neurons, astrocytes and microglial cells. (A) mRNA values are
presented as ratios of UCP to the house keeping gene GAPDH. Each data point represents the mean value 6 SD of three independent cultures each
from two litters of independent animals. (B) Western Blot analysis of UCP2 in 20 mg total cellular protein from primary cell cultures of neurons,
astrocytes and microglial cells. (C) Protein content in diverse populations of hematopoietic cells. Recombinant human UCP2 was used as a control.
20 mg of total cellular protein was loaded.
doi:10.1371/journal.pone.0041406.g004
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stimulation and is a critical point in decision on T-cell fate [56].
However, in view of the fact that UCP2 is present in the
mitochondrial membrane at very low level (Fig. 6), it is presently
not understandable whether UCP2 can catalyse a sufficiently high
proton leak to change a mitochondrial membrane potential
essentially [11]. Another plausible function is a fine-tuning of
reactive oxygen species (ROS), which at low levels were described
to regulate the expression of specific genes, to trigger signalling
pathways and to affect the activities of transcription factors during
the increased cell activity (for review [56]). UCP2 was also
proposed to regulate mitochondrial glutathione levels rather than
regulating ROS directly [26].
The low levels and high experimental variation of UCP2
detected in lungs, intestine and stomach imply that the protein’s
presence in these organs may be caused by accumulation of
immunocompetent tissues (such as bronchus-associated lymphoid
tissue (BALT), alveolar lymph nodes, Peyer’s Patches) and/or by
infiltration of activated immune cells due to contact with
pathogens, as previously proposed [16].
The most intriguing question is whether UCP2 is present in
brain. The detailed analysis of different cell types in the present
work shows UCP2 expression in microglia but not in neurons.
Because microglial cells are known to act in the immune defence of
the central nervous system [57], this finding supports the proposed
restriction of protein expression to the immune system. The
absence of UCP2 protein expression in neurons under physiolog-
ical conditions does not exclude the possibility that the protein is
expressed under pathological conditions. A protective function for
UCP2 has been proposed for a range of diseases, such as ischemia
[26,32], brain trauma [32], epilepsy [58–60], Parkinson’s disease
[61], diabetes [18], obesity [62], and anorexia nervosa [63].
Interestingly, not only brain degenerative processes, as previously
noted [64], but also all other pathophysiological models listed
above have a strong immunological background, accompanied by
a massive invasion of activated lymphocytes or the activation of
phagocytes/microglia [65]. Unfortunately, the proper discrimina-
tion of UCP2 expression in different cell types and in restricted
areas remains a difficult task, because to date there are no
antibodies suitable for the immunohistochemical analysis.
Several research groups have shown that UCP2 mRNA is
present only in specific neurons or distinct brain areas ([15,28,66]).
We cannot exclude the presence of UCP2 in small restricted areas
of brain. However, the UCP2 expression in single neurons
contradict our presented results and reports from other groups
showing that UCP2 abundance is limited to cells, which are able to
shift to glycolysis in order to ensure the rapidly increased
metabolism during proliferation such as lymphocytes, cancer and
embryonic stem cells [53,67–69] Because neurons do not display
Figure 5. Time course of UCP2 protein expression after unspecific stimulation (A), first re-stimulation (B) and second re-stimulation
(C) of isolated T-cells. As mitochondrial markers antibodies against VDAC, Hsp60 and SDHA were used. Cell protein loading was controlled by
detection of b-actin and GAPDH. The intensities of UCP2, VDAC, GAPDH, SDHA and Hsp60 were quantified as ratios to the intensity of b-actin. The
graph demonstrated the percentage change in expression at 6 hours after the first re-stimulation (D). Each data point represents the mean 6 SE of
three different WB.
doi:10.1371/journal.pone.0041406.g005
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a high proliferation rate leading to increase of aerobic glycolytic
metabolism we suggest that all neurons do not express UCP2 at
protein level.
In conclusion, our results support the hypothesis that the
function of UCP2 in lymphocytes may be related to the immune
challenge state and cell fate decision. Further investigations are
needed to analyse whether UCP2 is differently regulated in various
modes of T-cell activation and in different types of immune cells.
An understanding of UCP2 up-regulation mechanism and
function during immune cell activation is essential for defining
factors that may control the immune response in inflammatory
processes. Thus, UCP2 may represent a potential novel target in
diverse inflammatory conditions, such as autoimmune, neurode-
generative and inflammatory diseases.
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